These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36442912)

  • 1. Ensuring equity in the era of HLA-restricted cancer therapeutics.
    Smithy JW; Blouin A; Diamond LC; Postow M
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36442912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tebentafusp: First Approval.
    Dhillon S
    Drugs; 2022 Apr; 82(6):703-710. PubMed ID: 35364798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
    Chen LN; Carvajal RD
    Expert Rev Anticancer Ther; 2022 Oct; 22(10):1017-1027. PubMed ID: 36102132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors.
    Liu AW; Wei AZ; Maniar AB; Carvajal RD
    Expert Opin Biol Ther; 2022 Aug; 22(8):997-1004. PubMed ID: 35060440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.
    Wang Z; Xie Y; Wang JQ; Cheng Y; Fleishman J; Chen ZS; Chen Y
    Drugs Today (Barc); 2023 Mar; 59(3):179-193. PubMed ID: 36847626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of HLA-A*02:01 in the Brazilian population and its impact on uveal melanoma systemic treatment.
    de Melo AC; Lucena E; de Oliveira DCM; Viola JPB
    Oncologist; 2024 Aug; 29(8):e1098-e1099. PubMed ID: 38785402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tebentafusp in first-line melanoma trials: An outperforming outlier.
    Olivier T; Prasad V
    Transl Oncol; 2022 Jun; 20():101408. PubMed ID: 35364557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T Cell-Engaging Bispecific Antibodies Targeting gp100 and PRAME: Expanding Application from Uveal Melanoma to Cutaneous Melanoma.
    Reschke R; Enk AH; Hassel JC
    Pharmaceutics; 2024 Aug; 16(8):. PubMed ID: 39204391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
    Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
    J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma.
    Al Balushi K; Al Hadhrami A; Balushi HA; Al Lawati A; Das S
    Curr Drug Targets; 2024; 25(3):149-157. PubMed ID: 38115619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor lysis syndrome induced by tebentafusp.
    Ruf T; Leonhardt A; Anz D; Kunz WG; Röhrle N; Foerster P; Tomsitz D; French LE; Seegräber M; Heinzerling L
    Immunotherapy; 2023 Nov; 15(16):1363-1368. PubMed ID: 37661909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA expression in uveal melanoma: there is no rule without some exception.
    Jager MJ; Hurks HM; Levitskaya J; Kiessling R
    Hum Immunol; 2002 Jun; 63(6):444-51. PubMed ID: 12039519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma.
    Hua G; Carlson D; Starr JR
    J Adv Pract Oncol; 2022 Sep; 13(7):717-723. PubMed ID: 36199496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
    Nathan P; Hassel JC; Rutkowski P; Baurain JF; Butler MO; Schlaak M; Sullivan RJ; Ochsenreither S; Dummer R; Kirkwood JM; Joshua AM; Sacco JJ; Shoushtari AN; Orloff M; Piulats JM; Milhem M; Salama AKS; Curti B; Demidov L; Gastaud L; Mauch C; Yushak M; Carvajal RD; Hamid O; Abdullah SE; Holland C; Goodall H; Piperno-Neumann S;
    N Engl J Med; 2021 Sep; 385(13):1196-1206. PubMed ID: 34551229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tebentafusp: a first-in-class treatment for metastatic uveal melanoma.
    Howlett S; Carter TJ; Shaw HM; Nathan PD
    Ther Adv Med Oncol; 2023; 15():17588359231160140. PubMed ID: 36970111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.
    Middleton MR; McAlpine C; Woodcock VK; Corrie P; Infante JR; Steven NM; Evans TRJ; Anthoney A; Shoushtari AN; Hamid O; Gupta A; Vardeu A; Leach E; Naidoo R; Stanhope S; Lewis S; Hurst J; O'Kelly I; Sznol M
    Clin Cancer Res; 2020 Nov; 26(22):5869-5878. PubMed ID: 32816891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major histocompatibility antigens and antigen-processing molecules in uveal melanoma.
    Krishnakumar S; Abhyankar D; Sundaram AL; Pushparaj V; Shanmugam MP; Biswas J
    Clin Cancer Res; 2003 Sep; 9(11):4159-64. PubMed ID: 14519640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High frequency of allele-specific down-regulation of HLA class I expression in uveal melanoma cell lines.
    Hurks HM; Metzelaar-Blok JA; Mulder A; Claas FH; Jager MJ
    Int J Cancer; 2000 Mar; 85(5):697-702. PubMed ID: 10699951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma.
    Blom DJ; Luyten GP; Mooy C; Kerkvliet S; Zwinderman AH; Jager MJ
    Invest Ophthalmol Vis Sci; 1997 Aug; 38(9):1865-72. PubMed ID: 9286277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
    Kim CJ; Parkinson DR; Marincola F
    J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.